vismodegib Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
SMO receptor antagonists 4227 879085-55-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • erivedge
  • vismodegib
  • GDC-0449
  • RG3616
inhibits the hedgehog pathway and ABC transporters; has antineoplastic activity
  • Molecular weight: 421.29
  • Formula: C19H14Cl2N2O3S
  • CLOGP: 2.74
  • LIPINSKI: 0
  • HAC: 5
  • HDO: 1
  • TPSA: 76.13
  • ALOGS: -5.39
  • ROTB: 4

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 4 Hosey CM, Chan R, Benet LZ
Vd (Volume of distribution) 0.23 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.01 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.01 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 245 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
July 12, 2013 EMA Roche Registration Ltd
Jan. 30, 2012 FDA GENENTECH

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Muscle spasms 450.94 34.57 192 2554 122921 46560395
Alopecia 409.13 34.57 195 2551 162219 46521097
Dysgeusia 367.24 34.57 123 2623 40368 46642948
Ageusia 289.51 34.57 77 2669 11395 46671921
Weight decreased 114.16 34.57 96 2650 210753 46472563
Decreased appetite 106.40 34.57 89 2657 193747 46489569
Death 105.53 34.57 113 2633 335435 46347881
Squamous cell carcinoma 59.74 34.57 21 2725 7815 46675501
Fatigue 56.17 34.57 115 2631 608582 46074734
Basal cell carcinoma 52.12 34.57 25 2721 20462 46662854
Nausea 36.41 34.57 105 2641 687349 45995967

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Muscle spasms 964.38 34.51 348 3613 64490 29884027
Alopecia 760.36 34.51 218 3743 19057 29929460
Ageusia 619.54 34.51 158 3803 8795 29939722
Dysgeusia 516.00 34.51 172 3789 24629 29923888
Weight decreased 180.86 34.51 153 3808 150768 29797749
Squamous cell carcinoma 161.63 34.51 58 3903 10192 29938325
Decreased appetite 117.18 34.51 120 3841 149790 29798727
Basal cell carcinoma 91.69 34.51 44 3917 16024 29932493
Death 80.33 34.51 157 3804 357126 29591391
Fatigue 77.03 34.51 145 3816 320528 29627989
Taste disorder 55.93 34.51 20 3941 3463 29945054
Madarosis 48.26 34.51 10 3951 214 29948303
Constipation 47.35 34.51 66 3895 112840 29835677
Myalgia 40.12 34.51 50 3911 76617 29871900
Hypogeusia 39.65 34.51 11 3950 831 29947686
Nausea 37.10 34.51 104 3857 296853 29651664

Pharmacologic Action:

SourceCodeDescription
ATC L01XJ01 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
OTHER ANTINEOPLASTIC AGENTS
Hedgehog pathway inhibitors
FDA MoA N0000184148 Smoothened Receptor Antagonists
FDA EPC N0000184149 Hedgehog Pathway Inhibitor
CHEBI has role CHEBI:35610 cytostatic
CHEBI has role CHEBI:50905 teratogen
CHEBI has role CHEBI:66908 smoothened antagonist
CHEBI has role CHEBI:140921 hedgehog pathway inhibitor

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Basal cell carcinoma of skin indication 254701007

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 10.07 acidic
pKa2 4.25 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Smoothened homolog GPCR INHIBITOR Ki 7.79 CHEMBL CHEMBL
Sonic hedgehog protein Enzyme IC50 7.82 CHEMBL
Sonic hedgehog protein Enzyme IC50 8.52 CHEMBL
Smoothened homolog GPCR IC50 8.30 CHEMBL

External reference:

IDSource
D09992 KEGG_DRUG
4031330 VANDF
C3265872 UMLSCUI
CHEBI:66903 CHEBI
VIS PDB_CHEM_ID
CHEMBL473417 ChEMBL_ID
C538724 MESH_SUPPLEMENTAL_RECORD_UI
24776445 PUBCHEM_CID
9311 INN_ID
25X868M3DS UNII
6975 IUPHAR_LIGAND_ID
DB08828 DRUGBANK_ID
1242987 RXNORM
187095 MMSL
28293 MMSL
d07824 MMSL
014152 NDDF
703812008 SNOMEDCT_US
703813003 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
ERIVEDGE HUMAN PRESCRIPTION DRUG LABEL 1 50242-140 CAPSULE 150 mg ORAL NDA 31 sections